“We have submitted to the FDA in the US an application for emergency use authorization (Eua) for our bivalent vaccine mRna-1273.222” against Covid-19, targeted at Omicron 4-5, “for children and adolescents aged 12- 17. The presentation for Eua for 6-11 year olds has also been completed “. This was announced by Moderna via Twitter. The US company also informed that “the request for” ok “for children aged 6 months to 6 years should be completed by the end of the year. The vaccine mRna-1273.222 – recalls Moderna – is a bivalent vaccine that takes targets both the original Sars-CoV-2 strain and Omicron’s BA.4 / 5 subvariants. “
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.